Cargando…
Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer
The aim of this study was to address one of the major challenges of the actual era of nanomedicine namely, the bioavailability of poorly water soluble drugs such as Silymarin. We developed new, biodegradable, and biocompatible nanosized shuttles for Silymarin targeted delivery in colon-cancer cells....
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539237/ https://www.ncbi.nlm.nih.gov/pubmed/28824432 http://dx.doi.org/10.3389/fphar.2017.00508 |
_version_ | 1783254449008934912 |
---|---|
author | Radu, Ionut-Cristian Hudita, Ariana Zaharia, Catalin Stanescu, Paul O. Vasile, Eugenia Iovu, Horia Stan, Miriana Ginghina, Octav Galateanu, Bianca Costache, Marieta Langguth, Peter Tsatsakis, Aristidis Velonia, Kelly Negrei, Carolina |
author_facet | Radu, Ionut-Cristian Hudita, Ariana Zaharia, Catalin Stanescu, Paul O. Vasile, Eugenia Iovu, Horia Stan, Miriana Ginghina, Octav Galateanu, Bianca Costache, Marieta Langguth, Peter Tsatsakis, Aristidis Velonia, Kelly Negrei, Carolina |
author_sort | Radu, Ionut-Cristian |
collection | PubMed |
description | The aim of this study was to address one of the major challenges of the actual era of nanomedicine namely, the bioavailability of poorly water soluble drugs such as Silymarin. We developed new, biodegradable, and biocompatible nanosized shuttles for Silymarin targeted delivery in colon-cancer cells. The design of these 100 nm sized carrier nanoparticles was based on natural polymers and their biological properties such as cellular uptake potential, cytotoxicity and 3D penetrability were tested using a colon cancer cell line (HT-29) as the in vitro culture model. Comparative scanning electron microscopy (SEM) and atomic force microscopy (AFM) measurements demonstrated that the Silymarin loaded Poly(3-HydroxyButyrate-co-3-HydroxyValerate) (PHBHV) nanocarriers significantly decreased HT-29 cells viability after 6 and 24 h of treatment. Moreover, in vivo-like toxicity studies on multicellular tumor spheroids showed that the Silymarin loaded PHBHV nanocarriers are able to penetrate 3D micro tumors and significantly reduce their size. |
format | Online Article Text |
id | pubmed-5539237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55392372017-08-18 Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer Radu, Ionut-Cristian Hudita, Ariana Zaharia, Catalin Stanescu, Paul O. Vasile, Eugenia Iovu, Horia Stan, Miriana Ginghina, Octav Galateanu, Bianca Costache, Marieta Langguth, Peter Tsatsakis, Aristidis Velonia, Kelly Negrei, Carolina Front Pharmacol Pharmacology The aim of this study was to address one of the major challenges of the actual era of nanomedicine namely, the bioavailability of poorly water soluble drugs such as Silymarin. We developed new, biodegradable, and biocompatible nanosized shuttles for Silymarin targeted delivery in colon-cancer cells. The design of these 100 nm sized carrier nanoparticles was based on natural polymers and their biological properties such as cellular uptake potential, cytotoxicity and 3D penetrability were tested using a colon cancer cell line (HT-29) as the in vitro culture model. Comparative scanning electron microscopy (SEM) and atomic force microscopy (AFM) measurements demonstrated that the Silymarin loaded Poly(3-HydroxyButyrate-co-3-HydroxyValerate) (PHBHV) nanocarriers significantly decreased HT-29 cells viability after 6 and 24 h of treatment. Moreover, in vivo-like toxicity studies on multicellular tumor spheroids showed that the Silymarin loaded PHBHV nanocarriers are able to penetrate 3D micro tumors and significantly reduce their size. Frontiers Media S.A. 2017-08-02 /pmc/articles/PMC5539237/ /pubmed/28824432 http://dx.doi.org/10.3389/fphar.2017.00508 Text en Copyright © 2017 Radu, Hudita, Zaharia, Stanescu, Vasile, Iovu, Stan, Ginghina, Galateanu, Costache, Langguth, Tsatsakis, Velonia and Negrei. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Radu, Ionut-Cristian Hudita, Ariana Zaharia, Catalin Stanescu, Paul O. Vasile, Eugenia Iovu, Horia Stan, Miriana Ginghina, Octav Galateanu, Bianca Costache, Marieta Langguth, Peter Tsatsakis, Aristidis Velonia, Kelly Negrei, Carolina Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer |
title | Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer |
title_full | Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer |
title_fullStr | Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer |
title_full_unstemmed | Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer |
title_short | Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer |
title_sort | poly(hydroxybutyrate-co-hydroxyvalerate) (phbhv) nanocarriers for silymarin release as adjuvant therapy in colo-rectal cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539237/ https://www.ncbi.nlm.nih.gov/pubmed/28824432 http://dx.doi.org/10.3389/fphar.2017.00508 |
work_keys_str_mv | AT raduionutcristian polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT huditaariana polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT zahariacatalin polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT stanescupaulo polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT vasileeugenia polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT iovuhoria polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT stanmiriana polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT ginghinaoctav polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT galateanubianca polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT costachemarieta polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT langguthpeter polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT tsatsakisaristidis polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT veloniakelly polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer AT negreicarolina polyhydroxybutyratecohydroxyvaleratephbhvnanocarriersforsilymarinreleaseasadjuvanttherapyincolorectalcancer |